BTIG assumed coverage of ImmunityBio with a Buy rating and $13 price target. The stock has had a strong start to 2026, rising 318% year-to-date driven by 700% y/y growth for ANKTIVA in the US, EU conditional marketing approval, and approval for NSCLC in Saudi Arabia, and the firm believes further share appreciation from here will be led by continued ANKTIVA commercial execution and label expansion, the analyst tells investors in a research note.
